Mallinckrodt licenses Metasyn MRI agent
MRI contrast-agent developer Metasyn of Cambridge, MA, has landeda product development and licensing deal with Mallinckrodt Medicalof St. Louis for Metasyn's MS-325 gadolinium-based agent for MRangiography of coronary and peripheral arteries. The deal
MRI contrast-agent developer Metasyn of Cambridge, MA, has landeda product development and licensing deal with Mallinckrodt Medicalof St. Louis for Metasyn's MS-325 gadolinium-based agent for MRangiography of coronary and peripheral arteries. The deal alsoincludes other MRI vascular agents that may be developed by thecompanies.
Metasyn is beginning phase I clinical trials for MS-325, whichit hopes will replace other modalities, such as x-ray angiography,in cardiac assessment studies (SCAN 7/31/96). Mallinckrodt willmake an up-front $6 million licensing fee as part of the deal.
Mallinckrodt gains sales and marketing rights for MS-325 inall parts of the world except Japan. Metasyn granted licensingrights in that nation to Daiichi Pharmaceutical in April.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
